IgGenix, Inc., a clinical-stage biotechnology company pioneering innovative treatments for immune-mediated diseases, today ...

Despite the failure of an eczema trial in December, Q32 Bio is sticking with bempikibart. But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t be so lucky.

This new distribution center underscores our commitment to delivering high-quality functional antibodies to researchers ...

Intra-ImmuSG seeks to develop a safer and more effective cancer therapy via a combination of a targeted therapy and immunotherapy.

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Immunotherapy revolutionises cancer treatment by harnessing the immune system, offering targeted therapy with fewer side ...

Between February 3, 2025, and February 7, 2025, Essity Aktiebolag (publ) repurchased a total of 270,000 own Class B shares (ISIN: SE0009922164) under the framework of the buyback program as resolved ...

The future is bright for our bone marrow transplant program,” Dr. Hana Safah said. "We look forward to advancing blood cancer ...

SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug ...

Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...

Company plans to initiate a Phase 1/b trial in relapsed/refractory, locally advanced/metastatic bladder cancer by year-end ...

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...